| 产品描述: | MRTX-1719 is a potent, orally active, selective PRMT5•MTA complex inhibitor, with IC50 of 3.6 and 20.5 nM for PRMT5•MTA and PRMT5. MRTX-1719 binds to the PRMT5•MTA complex, with KD value of 0.14 pM. MRTX-1719 shows antineoplastic activity in vitro and in vivo, and can be used for cancer study |
| 靶点: |
PRMT5;HistoneMethyltransferase |
| 体外研究: |
MRTX-1719 (10 天) 在 MTAP 缺失的 HCT116 细胞而非野生型细胞中抑制 PRMT5 活性,IC50 为 8 nM。 MRTX1719 (10 天) 在 MTAP 敲除的 HCT116 细胞中的 IC50 值为 12 nM,对野生型 HCT116 细胞的 IC50 值为 890 nM |
| 体内研究: |
MRTX1719 (12.5-100 mg/kg/每天,口服,21天) 可降低 Lu-99 原位异种移植肿瘤的生长 Animal Model: Lu-99 (an MTAP/CDKN2A-deleted human lung cancer cell line ) xenograft tumor models Dosage: 12.5, 25, 50, and 100 mg/kg/d, 21 day Administration: Oral gavage Result: Reduced the tumor volume with 86% tumor growth inhibition (TGI) at 50 mg/kg and 88% TGI at 100 mg/kg. |
| 参考文献: |
1. Lars D Engstrom, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer. Cancer Discov. 2023 Aug 8;CD-23-0669. 2. Christopher R Smith, et al. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers. J Med Chem. 2022 Feb 10;65(3):1749-1766. 3. Targeting the genetic and immunological drivers of cancer. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.151 ml |
10.755 ml |
21.511 ml |
| 5 mM |
0.43 ml |
2.151 ml |
4.302 ml |
| 10 mM |
0.215 ml |
1.076 ml |
2.151 ml |
| 50 mM |
0.043 ml |
0.215 ml |
0.43 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |